Using Fluciclovine in the Recurrent Prostate Cancer Patient- David Schuster

Presentation from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.  (Length of lecture 57 minutes) 

In this lecture, David Schuster describes the mechanisms of uptake of the PET radiotracer fluciclovine and identifies normal biodistribution of fluciclovine.  In addition, Dr. Schuster discusses the FDA approval and clinical indication of fluciclovine and the clinical interpretive criteria of fluciclovine PET

Biography:
Dr. David Schuster is Director of the Division of Nuclear Medicine and Molecular Imaging and is a Georgia Research Alliance Distinguished Scientist. He serves in an NIH study section and reviews for medical journals. Dr. Schuster is widely published and has lectured nationally and internationally. Dr. Schuster is the recipient of the Society of Nuclear Medicine Tetalman Award and is also known for his co-authorship of the book “A Clinician’s Guide to Nuclear Medicine”.